Goldman Sachs Removes 'Sell' Rating from Biogen (BIIB)
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $214.35 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 12
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 12
Join SI Premium – FREE
Goldman Sachs upgraded Biogen (NASDAQ: BIIB) from Sell to Neutral, citing the unexpected success of key pipeline drug BG-12. The firm raised their price target from $52 to $109.
The analyst said the drug, "meaningfully strengthens the sustainability of BIIB’s core multiple sclerosis (MS) franchise."
Goldman is now assuming a base case of $2 billion in sales for BG-12 by 2015, however the drug could have potential between $1bn-$4bn depending on how the competitive landscape evolves.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Shares of Biogen closed at $99.70 yesterday.
The analyst said the drug, "meaningfully strengthens the sustainability of BIIB’s core multiple sclerosis (MS) franchise."
Goldman is now assuming a base case of $2 billion in sales for BG-12 by 2015, however the drug could have potential between $1bn-$4bn depending on how the competitive landscape evolves.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Shares of Biogen closed at $99.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades TIC Solutions (TIC) to Neutral
- JPMorgan Downgrades Bowman Consulting Group Ltd. (BWMN) to Underweight
- Baird Upgrades Parsons Corp. (PSN) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
